Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Adam on +44 1494 818 010 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Adam Woolley
Recruitment Consultant
+44 1494 818 010

Zenopa was extremely helpful at every stage of the recruitment process and kept me continually in the loop.
Nick , 2013

Novartis announces renewed commitment to eliminating leprosy

3 February 2012 00:00 in Pharmaceutical Company Product News

Novartis has announced that it will be expanding its commitment to eradicating leprosy, as part of a new global agreement.

Following a major meeting between pharmaceutical companies and government organisations, overseen by the Bill and Melinda Gates Foundation, Novartis has agreed to an expanded five-year drug donation scheme.

This will include the contribution of treatments worth $22.5 million (14.2 million pounds) up to 2020, as well as $2.5 million to help the World Health Organization deliver the medicines to around 850,000 patients.

Novartis has also pledged to take part in collaborative research to support the final push in eliminating the serious condition, rates of which have fallen dramatically in recent decades.

Joseph Jimenez, chief executive officer of Novartis, said: "We are proud to work with governments, international agencies, non-governmental organisations and the private sector to ensure that patients receive the treatment they need."

Last week, the company published its 2011 financial report, revealing a 16 percent year-over-year increase in sales last year.ADNFCR-8000103-ID-801283140-ADNFCR

Other news stories from 03/02/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd